C94.82 Other specified leukemias, in relapse

Name of the Condition

• Other specified leukemias, in relapse
• ICD-10 Code: C94.82

Summary

Other specified leukemias, in relapse refers to a heterogeneous group of malignant hematologic disorders where abnormal white blood cell proliferation has returned after a period of remission. These conditions involve dysregulated cell growth in the bone marrow or blood and may affect various cell lineages, depending on the specific subtype. Relapse indicates renewed disease activity, which can disrupt normal blood cell production and lead to organ dysfunction if not addressed promptly.

Causes

The exact cause involves genetic mutations or chromosomal abnormalities in blood-forming cells, leading to uncontrolled proliferation. Contributing factors may include environmental exposures (e.g., radiation, chemicals), genetic predispositions, or prior hematologic conditions. Relapse typically results from residual disease that was not fully eradicated during initial treatment or from the development of treatment-resistant clones.

Risk Factors

• Prior exposure to radiation or chemotherapy
• Genetic syndromes (e.g., Down syndrome)
• Family history of leukemia
• Certain chemical exposures (e.g., benzene)
• Advanced age
• Male gender
• History of myelodysplastic syndromes
• Inadequate or incomplete prior treatment
• Presence of minimal residual disease after remission

Symptoms

• Persistent or worsening fatigue or weakness
• Unexplained weight loss
• Fever or recurrent infections
• Easy bruising or bleeding
• Bone or joint pain
• Enlarged lymph nodes, liver, or spleen
• Shortness of breath

Diagnosis

Diagnosis involves a physical examination, followed by blood tests (complete blood count, peripheral smear) to identify abnormal cell counts or morphology. Bone marrow aspiration and biopsy are typically performed to assess for leukemic cell infiltration. Additional tests, such as flow cytometry, cytogenetics, or molecular studies, may be used to confirm relapse and guide treatment decisions.

Treatment Options

Treatment depends on the specific leukemia subtype, prior therapies, and patient factors. Options may include reinduction chemotherapy, targeted therapy, immunotherapy, or stem cell transplantation. Supportive care, such as blood transfusions, antibiotics, or growth factors, may be necessary to manage symptoms and complications.

Prognosis and Follow-Up

Prognosis varies based on the leukemia subtype, duration of remission, and response to retreatment. Regular follow-up with blood tests and bone marrow evaluations is essential to monitor for further relapse or treatment response. Long-term surveillance may be required to detect late effects of therapy or secondary malignancies.

Complications

• Severe infections due to neutropenia
• Bleeding or hemorrhage from thrombocytopenia
• Anemia and associated fatigue
• Organ dysfunction from leukemic infiltration
• Treatment-related toxicities (e.g., organ damage, secondary cancers)
• Psychological distress or emotional impact

Lifestyle & Prevention

• Avoid known environmental risk factors (e.g., benzene, radiation)
• Maintain a balanced diet and regular exercise to support overall health
• Practice good hygiene to reduce infection risk
• Follow recommended screening for high-risk individuals
• Adhere to prescribed treatment and follow-up schedules

When to Seek Professional Help

Seek immediate medical attention for symptoms such as uncontrolled bleeding, high fever, severe fatigue, or shortness of breath. Contact a healthcare provider if symptoms worsen or new symptoms develop, especially if previously in remission.

Tips for Medical Coders

Document the specific leukemia subtype and confirmation of relapse (e.g., clinical, laboratory, or imaging findings) to support code assignment. Ensure the medical record clearly indicates the relapse status, as this distinguishes C94.82 from other related codes. Verify that prior treatment history and remission duration are documented, as these may impact coding accuracy.